Daniela Regina de Carvalho Rocha

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
OBJECTIVE To describe the clinical characteristics of Latin American patients with metastatic renal cell carcinoma (mRCC) who experienced a progression-free survival (PFS) for at least 15 months(More)
465 Background: Prospective studies with sunitinib in mRCC have shown median progression-free survival (mPFS) of 11 months (first line) and 8.3 months (second line). In order to identify patients(More)
  • 1